1719-001: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
Oral PRMT5 inhibitor MRTX1719
Phase 1 - advanced MTAP deleted solid tumor that has continued to grow despite treatment with standard anti-cancer therapies.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology
Contact us today to request an appointment.Virtual & Telemedicine available.